<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181320</url>
  </required_header>
  <id_info>
    <org_study_id>Granulox01 (PD-568268)</org_study_id>
    <nct_id>NCT04181320</nct_id>
  </id_info>
  <brief_title>A Multicentre European Study to Evaluate Granulox® Used in the Treatment Pathway of Predominantly Chronic Venous Leg Ulcers (VLUs).</brief_title>
  <acronym>Granulox01</acronym>
  <official_title>Multicentre, Prospective, Randomized, Open-label, Assessor Blinded Study to Evaluate Granulox® Used as Adjunct Therapy to Defined Standard of Care vs. Defined Standard of Care for the Treatment of Predominantly Chronic Venous Leg Ulcers (VLUs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigation is designed as an open label, randomized, prospective, assessor blinded,&#xD;
      multi centre investigation.&#xD;
&#xD;
      254 evaluable subjects will be randomized to either standard of care group or standard of&#xD;
      care with Granulox added as an adjunct therapy in predominantly venous leg ulcer subjects.&#xD;
      Standard of care wound management will be completed, including wound cleansing, debridement&#xD;
      if necessary and application of a suitable dressing and compression system until complete&#xD;
      wound closure.&#xD;
&#xD;
      The study will be divided into two phases. Firstly, a two week run-in period to ensure&#xD;
      compliance to compression therapy followed by a 20 weeks treatment period starting with&#xD;
      randomization and allocation of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed to verify previous clinical findings and to pinpoint clinically&#xD;
      relevant efficacy, associated to intended use of Granulox® as a therapy added to a defined&#xD;
      standard of care in the management of chronic VLUs. The most relevant outcome is considered&#xD;
      to be an increase in healing of chronic VLUs over a period of 20 weeks.&#xD;
&#xD;
      This is a multi-centre European open label randomised 2-arm parallel group study. The study&#xD;
      will include multiple European counties (e.g. France, Germany, UK, Poland, Croatia and Czech&#xD;
      Republic), with approximately 2-7 clinics per country.&#xD;
&#xD;
      The study will run with a two-phase set-up, with a 14 days run-in period and a an up to 20&#xD;
      weeks treatment period starting with randomization and allocation of treatment. Confirmation&#xD;
      of wound closure is further assessed after a 15 day followup period.&#xD;
&#xD;
      The primary objective of the study is to compare wound healing between management of chronic&#xD;
      VLUs with or without added Granulox®. The main efficacy criterion is Confirmed Complete wound&#xD;
      Closure (CCC).&#xD;
&#xD;
      Secondary objectives include comparisons of management of chronic VLUs with or without added&#xD;
      Granulox® with regards to:&#xD;
&#xD;
        -  Wound healing by means of Possible Complete wound Closure (PCC), Wound Area Regression&#xD;
           (WAR), time to healing, trajectories, pressure ulcer scale for healing (PUSH) score, and&#xD;
           clinical assessment.&#xD;
&#xD;
        -  Patient Reported Outcomes (PRO) for health-related quality of life (HRQoL)/quality of&#xD;
           life (QoL), pain and pain intensity, and impression of change.&#xD;
&#xD;
        -  Acceptability of and compliance to therapy.&#xD;
&#xD;
        -  Cost-effectiveness.&#xD;
&#xD;
        -  Safety by means of Adverse Events (AE) and Serious Adverse Events (SAE) reporting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, prospective, randomized, European open label, assessor blinded, 2-arm parallel group study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Wound closure (CCC and PCC) will be assessed through ulcer photos by 2 independent and experienced clinicians unaware of treatment allocation (blind review).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete confirmed wound closure (CCC) will be measured and compared for 254 subjects divided into standard of care versus standard of care with Granulox.</measure>
    <time_frame>20 weeks</time_frame>
    <description>Derived by two blinded quantifications of 100% re-epithelialization by PictZar, 15 days (+/- 3 days) apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healing time</measure>
    <time_frame>20 weeks</time_frame>
    <description>Calculated from time in days from baseline to the first observation of CCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound status</measure>
    <time_frame>20 weeks</time_frame>
    <description>Wound size measured, i.e. width, length, circumference or perimeter, via PictZar®.&#xD;
Exudate amount and nature.&#xD;
Tissue (i.e. fibrinous, granulation, epithelisation) type, i.e. area and percentage from total wound.&#xD;
Skin condition, i.e. peri-wound, redness/irritation/eczema, maceration, blistering, stripping, trauma.&#xD;
Local infection status, i.e. pain, perilesional skin erythema, oedema, malodour, levels of exudate.&#xD;
Cleansing specification.&#xD;
Debridement specification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Area Regression (WAR)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Calculated variables 90WAR (i.e. 90% WAR from baseline, based on wound photos) and 50WAR (i.e. 50% WAR from baseline, based on wound photos).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of possible confirmed wound closure (PCC) will be measured and compared for 254 subjects divided into standard of care versus standard of care with Granulox.</measure>
    <time_frame>20 weeks</time_frame>
    <description>derived from one measurements of 100% reepithelialization by via PictZar®.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing trajectories</measure>
    <time_frame>20 weeks</time_frame>
    <description>Calculated progression of the re-epithelialization wave over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure Ulcer Scale for Healing tool</measure>
    <time_frame>20 weeks</time_frame>
    <description>Wound changes over time will be captured by the Pressure Ulcer Scale for Healing tool. Total score from 0 to 17 where the lower the score the better the outcome e.g when the wound has closed, score as '0'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blind assessment of wound healing</measure>
    <time_frame>20 weeks</time_frame>
    <description>Assessor-blinded clinical verification of CCC and PCC based on patient-series of wound photos assessed by independent and experienced clinicians, unaware of treatment allocation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life assessment by EQ-5D-5L</measure>
    <time_frame>20 weeks</time_frame>
    <description>Patient report outcome questionnaire to evaluate health and quality of life. The higher the score the better the outcome e.g 100 means the best health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound specific Quality of Life assessment by Wound-QoL</measure>
    <time_frame>20 weeks</time_frame>
    <description>Patient report outcome questionnaire to evaluate wound specific quality of life. A 5 point scale based on 17 questions of the wound in the last seven days from 'not at all' to 'very much'. The lower the score at 'not at all' the better the outcome e.g my wound hurt (not at all).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale (NRS)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Patient report outcome questionnaire to evaluate pain. A total score range of 0 - 10. The lower the score the better the outcome e.g 0 is no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of care</measure>
    <time_frame>20 weeks</time_frame>
    <description>Assessment of acceptability of care by means of a 5-item scale (e.g. very poor, poor, average, good, very good) where very good is a better outcome. This will be performed at the final visit only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of care</measure>
    <time_frame>20 weeks</time_frame>
    <description>Assessment of ease of care by means of a 5-item scale (e.g. very poor, poor, average, good, very good) where very good is a better outcome. This will be performed at the final visit only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient compliant to venous compression</measure>
    <time_frame>20 weeks</time_frame>
    <description>Evaluation will be based on a 3 point scale from fully compliance, moderately compliance or no compliance to compression therapy where fully compliance is a better outcome. Compliance to compression therapy will be defined as the following:&#xD;
Fully compliance (defined as 7/7 days) = continue in study&#xD;
Moderately compromised compliance (defined as 2 or 3 days maximum without compression) = continue in study&#xD;
No compliance (defined as &gt;3 without compression) = discontinue from study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Effectiveness</measure>
    <time_frame>20 weeks</time_frame>
    <description>Collection of cost parameters such as micro costing and resource utilization will be made in the study. These include:&#xD;
Wound care consumables associated with dressings (captured both at site by investigator and in the patient specific diary by the study nurse)&#xD;
Frequency of dressings changes (captured both at site by investigator and in the patient specific diary by the study nurse). In addition, reporting of adverse events (i.e. infection and hospitalization) will be used as a basis for economic information together with country-specific costs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Venous Leg Ulcer Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will recieve standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venous Leg Ulcer Standard of Care with Granulox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will recieve standard of care treatment with Granulox added as an adjunct therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venous Leg Ulcer Standard of Care with Granulox</intervention_name>
    <description>Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.</description>
    <arm_group_label>Venous Leg Ulcer Standard of Care with Granulox</arm_group_label>
    <other_name>Granulox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed consent to participate.&#xD;
&#xD;
          2. No planned hospitalization in the forthcoming 20 weeks.&#xD;
&#xD;
          3. Male or female (women of childbearing age must have an acceptable method of birth&#xD;
             control).&#xD;
&#xD;
          4. Age &gt;18 years.&#xD;
&#xD;
          5. Recent (less than 12 months) doppler or duplex colour ultrasonography compatible with&#xD;
             chronic venous insufficiency.&#xD;
&#xD;
          6. ABPI (less than 3 months) ≥0.7 for both legs. If ABPI &gt;1.4, then big toe pressure&#xD;
             &gt;60mmHg is required or an alternative measurement verifying normal distal arterial&#xD;
             flow.&#xD;
&#xD;
          7. At least one or more supra- or peri-malleolar leg ulcers and no foot ulcer or another&#xD;
             chronic wound.&#xD;
&#xD;
          8. In case of two or more ulcers, select ulcer with the highest PUSH score at&#xD;
             randomization and treat the non-selected ulcer in the same way as ulcers in the&#xD;
             control group (standard of care).&#xD;
&#xD;
          9. In case of two or more ulcers on the same limb, ensure that the distance between each&#xD;
             ulcer is 3 cm as measured from the margins of each ulcer that are closest to one&#xD;
             another.&#xD;
&#xD;
         10. Wound duration ≥ 8 weeks and ≤60 months.&#xD;
&#xD;
         11. At randomization, the ulcer area should be 3 cm2 - 70 cm² and should not have&#xD;
             decreased by more than 30% during the 2-week run-in period.&#xD;
&#xD;
         12. Less than 50% of the wound area should be covered with fibrinous tissue at&#xD;
             randomization and after debridement.&#xD;
&#xD;
         13. Patients considered as compliant/adherent to the compression device during the run-in&#xD;
             period (i.e. no more than 2 days without compression over the 2-week run-in period).&#xD;
&#xD;
         14. No clinically significant comorbidities requiring the use of systemic steroids or any&#xD;
             cytotoxic or immunosuppressive agents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infected ulcer according to the judgment of the investigator defined as any wound&#xD;
             condition requiring the prescription or continuation of systemic antibiotic therapy at&#xD;
             randomization.&#xD;
&#xD;
          2. Circumferential wounds.&#xD;
&#xD;
          3. Wound covered fully or partially by necrotic tissue (black tissue).&#xD;
&#xD;
          4. Patients who will have problems following the protocol, especially compression&#xD;
             therapy.&#xD;
&#xD;
          5. Patients included in another on-going clinical investigation, or patients who have&#xD;
             participated in a clinical investigation during the past 30 days.&#xD;
&#xD;
          6. Wounds treated with dressings containing an active component (e.g. silver,&#xD;
             nanooligosaccharide factor (NOSF), charcoal, chlorhexidine, iodine or ibuprofen) 14&#xD;
             days prior to study enrollment.&#xD;
&#xD;
          7. Patient with a systemic infection not controlled by suitable antibiotic treatment.&#xD;
&#xD;
          8. Current treatment with radiotherapy, chemotherapy, immunosuppressant drugs or high&#xD;
             doses of oral corticosteroids (&gt;10 mg Predinsolone or equivalent) if any.&#xD;
&#xD;
          9. Patient with deep vein thrombosis within 3 months prior to inclusion.&#xD;
&#xD;
         10. Known allergy/hypersensitivity to the ingredients of the dressings and/or Granulox®.&#xD;
&#xD;
         11. Malignant wounds.&#xD;
&#xD;
         12. Endovenous surgery planned or performed within the past 30 days.&#xD;
&#xD;
         13. Primary lymphoedema caused by congenital/developmental defect, i.e. Milroy's disease&#xD;
             (congenital lymphedema), Meige's disease (lymphedema praecox), or Late-onset&#xD;
             lymphedema (lymphedema tarda).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Dissemond, Professor Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina Chowdhury</last_name>
    <phone>+44 (0)7769 907654</phone>
    <email>sabrina.chowdhury@molnlycke.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinicki odjel za vaskularnu kirurgiju</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frano Simic, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomislav Salamon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zavod za vaskularnu kirurgiju</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vedran Pazur, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salvatella s.r.o.</name>
      <address>
        <city>Třinec</city>
        <state>Dolni Lomna</state>
        <zip>739 61</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Stryja,, MUDr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHIR-Chirurgické oddeleni</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radovan Cech, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U Nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martina Zemlickova, MUDr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillippe Leger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <state>La Tronche</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Blaise, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Nord Franche-Comte</name>
      <address>
        <city>Belfort</city>
        <state>Trevenans</state>
        <zip>90015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragos Popescu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Rothschild - AP-HP</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Meaume, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department od Dermatology, Venerology and Allergology, University of Essen</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Dissemond, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Drees.K.CH.Busch/v.d.Ecken</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Busch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus - Klinik fuer Dermatologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Aschoff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Erfurt Berge</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oberhausen Sterkrade (Zweigpraxis)</name>
      <address>
        <city>Oberhausen</city>
        <zip>46145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siamak Pourhassan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Korhaz</name>
      <address>
        <city>Gyöngyös</city>
        <state>Heves</state>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Makai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DermaMed Research Kft</name>
      <address>
        <city>Orosháza</city>
        <state>Oroshaza</state>
        <zip>5900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edina Nemes, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinexpert Kft</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltán Kökény, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MDC Clinic Egészégugyi és Diagnosztikai Központ</name>
      <address>
        <city>Budapest</city>
        <zip>1047</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem, Klinikai Kozpont, Borgyogyaszati Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4002</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Szegedi, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc oktatókórház és rendelöintézet</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleonora Harcsa, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BKS Research Kft</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Csaba Hajdu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uslugi Medyczne PRO-MED Sp. z.o.o</name>
      <address>
        <city>Gliwice</city>
        <state>Gliwicie</state>
        <zip>44109</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Rogalska, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PLEJADY</name>
      <address>
        <city>Kraków</city>
        <state>Krakow</state>
        <zip>30363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Belowski, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 1 im. dr. A. Jurasza w Bydgoszczy Poradnia Leczenia Ran Przewleklych</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arkadiusz Jawien, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nzoz Gam-Med</name>
      <address>
        <city>Kielce</city>
        <zip>25315</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Rostalski, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Braci Wieniawskick 12B</name>
      <address>
        <city>Lublin</city>
        <zip>20-844</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Niedziela, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MIKOMED Sp. Z.o.o.</name>
      <address>
        <city>Łódź</city>
        <zip>94238</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek S Mikosinski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hull University Teaching Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Chetter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Accelerate CIC</name>
      <address>
        <city>London</city>
        <zip>E8 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Staines</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central and North West London NHS</name>
      <address>
        <city>London</city>
        <zip>NW1 3AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luxmi Dhoonmoon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Welsh Wound innovation Centre</name>
      <address>
        <city>Pontyclun</city>
        <zip>CF72 8UX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Ivins, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulox</keyword>
  <keyword>venous ulcers</keyword>
  <keyword>wound healing</keyword>
  <keyword>wound reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

